ALB and Huntington disease: For evaluation of the combined impact of baseline hs-CRP/Alb and fluctuation of hs-CRP/Alb on the long-term prognosis of chronic HD patients, total patients (n = 284) were divided into “high” (n = 142) and “low” (n = 142) groups based on the median baseline hs-CRP/Alb (data of February 2008).